Interferon gamma (IFN-γ) negative CD4+ and CD8+ T-cells can produce immune mediators in response to viral antigens.
Adenoviridae
Antigens, Viral
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Cohort Studies
Cross-Sectional Studies
Enzyme-Linked Immunospot Assay
Flow Cytometry
HIV Infections
/ immunology
HIV-1
Humans
Immunologic Factors
/ immunology
Interferon-gamma
/ immunology
Interleukin-2
/ immunology
Leukocytes, Mononuclear
/ immunology
Lymphocyte Activation
Peptides
/ immunology
Perforin
/ immunology
Tumor Necrosis Factor-alpha
/ immunology
ELISpot assay
Flow cytometry
HIV-1
IFN-γ negative T-cells
T-cell responses
Vaccines
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
03 01 2019
03 01 2019
Historique:
received:
27
03
2018
revised:
06
11
2018
accepted:
12
11
2018
pubmed:
22
11
2018
medline:
7
6
2019
entrez:
22
11
2018
Statut:
ppublish
Résumé
Evaluation of antigen-specific T-cell responses to viral antigens is frequently performed on IFN-γ secreting cells. However, T-cells are capable of producing many more functions than just IFN-γ, some of which, like Perforin, are associated with immune protection in HIV-1 disease elite controllers. We evaluated the extent of missed T-cell functions when IFN-γ secretion is used as a surrogate marker for further evaluation of T-cell functions. Intracellular cytokine staining assay and flow cytometry were used to assess peripheral blood mononuclear cells (PBMCs) from 31 HIV-infected ART-naive individuals for the extent to which gated CD4+ and CD8+ IFN-γ producing and non-producing T-cells also secreted IL-2, Perforin, and TNF-α functions. Similarly, the extent of missed virus-specific responses in IFN-γ ELISpot assay negative T-cells from 5 HIV-1 uninfected individuals was evaluated. Cells from HIV-infected individuals were stimulated with pooled consensus group M (Con M) peptides; and those from healthy individuals were stimulated with pooled adenovirus (Ad) peptides. Overall, frequencies of virus-specific IFN-γ secreting CD4+ and CD8+ cells were low. Proportions of IFN-γ negative CD4+ expressing IL-2, Perforin, or TNF-α to Con M were significantly higher (5 of 7 functional profiles) than the corresponding IFN-γ positive CD4+ (0 of 7) T-cell phenotype, p = 0.02; Fisher's Exact test. Likewise, proportions of CD8+ T-cells expressing other functions were significantly higher in 4 of the 7 IFN-γ negative CD8+ T-cells. Notably, newly stimulated Perforin, identified as Perforin co-expression with IL-2 or TNF-α, was significantly higher in IFN-γ negative CD8+ T-cell than in the positive CD8+ T-cells. Using SEB, lower responses in IFN-γ positive cells were most associated with CD4+ than CD8+ T-cells. These findings suggest that studies evaluating immunogenicity in response to HIV and Adenovirus viral antigens should not only evaluate T-cell responsiveness among IFN-γ producing cells but also among those T-cells that do not express IFN-γ.
Identifiants
pubmed: 30459072
pii: S0264-410X(18)31547-0
doi: 10.1016/j.vaccine.2018.11.024
pmc: PMC6290111
pii:
doi:
Substances chimiques
Antigens, Viral
0
Immunologic Factors
0
Interleukin-2
0
Peptides
0
Tumor Necrosis Factor-alpha
0
Perforin
126465-35-8
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-122Subventions
Organisme : Medical Research Council
ID : MC_U950097145
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00027/1
Pays : United Kingdom
Organisme : NIMH NIH HHS
ID : R25 MH064712
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH123256
Pays : United States
Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Nature. 2001 Mar 1;410(6824):106-11
pubmed: 11242051
BioDrugs. 1998 Sep;10(3):215-25
pubmed: 18020597
Eur J Immunol. 2008 Feb;38(2):350-63
pubmed: 18200635
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13812-7
pubmed: 11095721
PLoS Med. 2006 Oct;3(10):e403
pubmed: 17076553
J Virol. 2003 Jul;77(13):7330-40
pubmed: 12805431
Blood. 2000 Nov 1;96(9):3094-101
pubmed: 11049989
AIDS Res Hum Retroviruses. 2012 Apr;28(4):384-92
pubmed: 21867408
J Immunol Methods. 2007 Mar 30;320(1-2):18-29
pubmed: 17222422
Cytometry A. 2014 Nov;85(11):969-77
pubmed: 25044796
J Virol. 2011 Feb;85(3):1275-86
pubmed: 21084478
J Immunol. 2009 Apr 15;182(8):4751-61
pubmed: 19342652
AIDS Res Hum Retroviruses. 2016 Mar;32(3):237-46
pubmed: 26548707
J Virol. 2010 Apr;84(8):3868-78
pubmed: 20130059
J Clin Invest. 2011 Nov;121(11):4322-31
pubmed: 21965332
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
J Exp Med. 1992 Sep 1;176(3):739-50
pubmed: 1512539
Vaccine. 2017 Apr 4;35(15):1898-1906
pubmed: 28285985
J Virol. 2014 Feb;88(3):1819-24
pubmed: 24227857
AIDS. 2013 Jan 2;27(1):17-27
pubmed: 23079801
PLoS Pathog. 2010 Mar 05;6(3):e1000798
pubmed: 20221423
Clin Exp Immunol. 1992 Oct;90(1):6-12
pubmed: 1395102
J Exp Med. 1999 Mar 15;189(6):991-8
pubmed: 10075982
Blood. 2002 Apr 1;99(7):2505-11
pubmed: 11895786
J Virol. 2010 May;84(10):4998-5006
pubmed: 20200250
J Exp Med. 2009 Jun 8;206(6):1253-72
pubmed: 19487423
Cells. 2012 May 10;1(2):111-26
pubmed: 24710418
AIDS. 2011 Mar 13;25(5):679-89
pubmed: 21297424
AIDS Res Hum Retroviruses. 2007 Jan;23(1):67-76
pubmed: 17263635
AIDS. 2005 Jul 22;19(11):1165-72
pubmed: 15990569
PLoS One. 2014 Aug 05;9(8):e104235
pubmed: 25093660
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
J Immunol. 2009 May 1;182(9):5560-9
pubmed: 19380804
PLoS Pathog. 2010 May 27;6(5):e1000917
pubmed: 20523897
Am J Trop Med Hyg. 2005 Jul;73(1):44-9
pubmed: 16014830
J Infect Dis. 2004 Nov 1;190(9):1692-6
pubmed: 15478077
Mol Cell Biol. 1995 May;15(5):2359-66
pubmed: 7739519
Proc Natl Acad Sci U S A. 2012 Jun 19;109(25):9983-8
pubmed: 22665800
J Virol. 2010 Oct;84(20):10522-32
pubmed: 20686035
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Vaccine. 2014 Jun 24;32(30):3787-95
pubmed: 24837770
J Virol. 2009 Aug;83(15):7641-8
pubmed: 19458000